Kathryn J. Collier, Director at Regulus Therapeutics Inc. (RGLS), bought 4,000 shares at $1.82 ($7K) on 2024-07-25, disclosed to the SEC on 2024-07-29.
Open-market purchase of $7k RGLS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.